Non-Compliance with U.S. FDA Regulations
A practical guide for domestic and foreign manufacturers, exporters, importers and distributors of food, dietary supplements, cosmetics, OTC and prescription drugs, medical devices and other FDA-regulated products.
Non-compliance can affect more than one shipment
- Products may be detained, refused, recalled or seized.
- A facility may receive inspection observations, an Untitled Letter or a Warning Letter.
- Future imports may be detained without physical examination under an Import Alert.
- Commercial partners may suspend listings, payments, distribution or marketplace access.
- Management may need a documented corrective and preventive action program before operations can normalize.
Compliance is a continuing business obligation
Companies that manufacture, process, pack, label, hold, import, export or distribute FDA-regulated products operate within a complex system of statutes, regulations, guidance documents, registration obligations, product-specific requirements and enforcement policies. Compliance is not completed by filing a registration once, appointing a U.S. Agent or placing an FDA-related phrase on a website. It requires an operating system that consistently connects product classification, facility registration, product listing, quality controls, supplier oversight, labeling, claims, recordkeeping, complaint handling, adverse-event reporting and import documentation.
Non-compliance can arise in a domestic factory in the United States or at a foreign facility in Europe, Asia, Latin America or Africa. The same product may involve several responsible parties: a foreign manufacturer, a private-label owner, a U.S. importer, an Initial Importer for medical devices, an FSVP importer for food, a distributor, an Amazon seller, a customs broker, a fulfillment center and a retailer. A breakdown by one participant can expose the entire supply chain to delay and enforcement risk.
The U.S. Food and Drug Administration generally seeks to protect public health by identifying violations, requesting corrective action and, where appropriate, using administrative, civil or criminal enforcement tools. Warning Letters are an important means of communicating violations of regulatory significance, but FDA does not have to issue a Warning Letter before taking enforcement action. A company therefore should not treat the absence of a public letter as proof that its products, records or facility comply.
This article explains how FDA non-compliance develops, the consequences that domestic and foreign companies may face, the most common weaknesses across product categories and the services that qualified FDA consultants in the United States may provide. It is written for business leaders, regulatory personnel, quality managers, exporters, importers, distributors and marketplace sellers that need to prevent problems or respond when an issue has already occurred.
What FDA non-compliance means
A product may be commercially successful and still violate U.S. law. FDA compliance is determined by the applicable legal requirements, not by sales volume, customer reviews, foreign certifications or the fact that similar products appear online.
Adulteration
A product may be adulterated because of contamination, insanitary manufacturing conditions, inadequate controls, failure to meet quality requirements, use of an unsafe ingredient or manufacture in a facility that limits or refuses an FDA inspection. Adulteration does not always mean visible damage. Deficient systems, unreliable laboratory data or an inability to demonstrate control can be enough to create serious regulatory concerns.
Misbranding
A product may be misbranded when required information is missing, inaccurate, misleading, not prominent enough or presented in the wrong format. Examples include an incorrect statement of identity, undeclared allergens, deficient directions, missing warnings, inaccurate net quantity, unsupported “FDA approved” implications, improper drug facts, an incorrect Nutrition Facts panel or claims that change the legal category of the product.
Unauthorized marketing
Some products require premarket authorization, clearance, approval, notification or compliance with a monograph before lawful marketing. A medical device may require a 510(k), De Novo authorization or PMA. A drug may be an unapproved new drug. A cosmetic promoted to treat disease may become a drug. A conventional food promoted with impermissible disease claims may create a different regulatory problem.
Registration is not product approval. Facility registration, device listing, drug listing, cosmetic facility registration or product listing should not be presented as FDA endorsement. Companies must understand what FDA has actually approved, cleared, authorized, registered or merely received.
How non-compliance is discovered
FDA inspections and record requests
FDA may inspect domestic or foreign establishments and review production areas, warehouses, laboratories, quality systems, electronic records, batch documentation, complaints, adverse-event files, supplier controls and corrective actions. Depending on the product and legal authority involved, FDA may also request records before or instead of an inspection. Refusing, delaying, limiting or obstructing an inspection can create an independent and highly serious compliance issue.
Import entry screening
Imported FDA-regulated products are screened electronically when offered for entry. FDA may review manufacturer identities, registration and listing status, product codes, prior shipment history, labeling, laboratory findings, country and facility risk, Import Alert status and entry documentation. A single inaccurate data element may cause delay, while a product that appears violative may be detained.
Sampling and laboratory analysis
FDA may collect samples and test for pathogens, undeclared active ingredients, heavy metals, pesticides, potency, sterility, identity, decomposition, illegal colors or other hazards. A failed sample can trigger a detention, recall discussion, Warning Letter, Import Alert recommendation or expanded review of related products and facilities.
Complaints and adverse events
Consumer complaints, medical device reports, serious adverse-event reports, whistleblower allegations and information from health professionals can lead to inspections or investigations. An inadequate complaint procedure may compound the original problem because FDA expects firms to evaluate signals, investigate root causes and report events when required.
Online marketing and marketplace surveillance
Websites, social media, influencer content, product listings, videos and paid advertisements can reveal disease claims, unauthorized indications, misleading safety representations or claims that conflict with approved labeling. A product’s intended use may be determined from the totality of its promotional presentation, not only from words printed on the package.
Partner and supply-chain audits
Importers, distributors, retailers, pharmacy chains, marketplaces and large customers increasingly require regulatory documentation. Their reviews may uncover expired registrations, incomplete supplier verification, missing test reports, absent U.S. contacts, labeling defects or inconsistent manufacturing records before FDA becomes directly involved.
Common violations by product category
Food and beverages
- Failure to register a food facility or renew during the required period.
- Inadequate hazard analysis and risk-based preventive controls.
- Missing or ineffective sanitation, allergen, process or supply-chain controls.
- Failure to comply with seafood HACCP, juice HACCP or applicable low-acid canned food and acidified food requirements.
- Undeclared major food allergens, inaccurate Nutrition Facts or misleading nutrient and health claims.
- Failure by the U.S. FSVP importer to evaluate hazards and verify foreign suppliers.
- Pathogens, filth, pesticide residues, unsafe additives or insanitary transportation and storage.
Dietary supplements
- Failure to establish specifications for identity, purity, strength, composition and contamination limits.
- Incomplete master manufacturing records, batch production records or quality-control review.
- Failure to conduct appropriate identity testing of dietary ingredients.
- Unsupported structure/function claims or claims to diagnose, treat, cure or prevent disease.
- Use of an ingredient that creates new dietary ingredient or drug-related concerns.
- Inadequate complaint handling and serious adverse-event reporting.
- Labels that omit required Supplement Facts, ingredient or domestic contact information.
Cosmetics and OTC cosmetics
- Microbial contamination, unsafe ingredients or manufacturing under insanitary conditions.
- Failure to meet applicable Modernization of Cosmetics Regulation Act obligations.
- Missing facility registration, product listing, safety substantiation or adverse-event processes where required.
- Labels lacking required identity, net quantity, ingredient declaration, business information or warnings.
- Claims that convert a conventional cosmetic into a drug, such as treating acne, eczema, infection, pain or hair loss.
- Failure of sunscreen, fluoride toothpaste, antiperspirant, antidandruff or other OTC drug-cosmetic products to meet drug requirements.
Human drugs and OTC drugs
- Marketing an unapproved new drug or an OTC drug that does not conform to an applicable legal pathway.
- CGMP deficiencies involving investigations, laboratory controls, data integrity, cleaning, stability, validation or quality oversight.
- Failure to register an establishment, list products accurately or update discontinued listings.
- Inadequate Drug Facts labeling, missing warnings or promotional claims inconsistent with lawful use.
- Failure to investigate out-of-specification results or unexplained discrepancies.
- Use of unreliable contract laboratories or suppliers without adequate qualification and oversight.
Medical devices
- Marketing without required clearance, approval or authorization.
- Failure to register an establishment, list devices or identify applicable U.S. importers.
- Quality system deficiencies involving design, production, supplier controls, nonconforming product, CAPA or records.
- Failure to submit Medical Device Reports or properly evaluate complaints.
- Incorrect labeling, inadequate directions, unsupported performance claims or missing Unique Device Identification requirements.
- Failure to comply with corrections and removals, tracking or radiation-emitting product requirements when applicable.
Importers and distributors
- Using incorrect manufacturer, product code, intended use, affirmation of compliance or registration data at entry.
- Importing from an unregistered or unlisted establishment.
- Failure to maintain required FSVP, Initial Importer, complaint, traceability or recall responsibilities.
- Distributing products after learning of contamination, labeling defects or unauthorized claims.
- Assuming that a customs broker or foreign supplier has accepted all FDA responsibilities.
- Inability to rapidly identify affected lots, customers, warehouses and consignees.
Domestic and foreign companies face different operational consequences
Domestic establishments
A U.S. manufacturer, packer, warehouse, importer or distributor may face an inspection, Form FDA 483 observations, an Untitled Letter, a Warning Letter, recall pressure, administrative detention, product seizure, injunction, civil money penalties, suspension of registration in certain circumstances or criminal investigation. Domestic firms must also manage employee interviews, access to records, state regulators, customer notifications and continuity of operations.
Even when FDA allows voluntary correction, the business effect can be immediate. Customers may stop accepting product, insurers may request information, lenders may reassess risk and marketplaces may deactivate listings. A delayed or superficial response can persuade FDA that management lacks adequate control.
Foreign establishments
European, Asian, Latin American and African companies may face all the technical expectations applicable to their product category, together with the additional consequences of the U.S. import system. FDA may detain a shipment that appears violative. If the company does not overcome the appearance of violation within the available process, the shipment may be refused and generally must be exported or destroyed under supervision.
A foreign manufacturer may also be placed on an Import Alert, allowing future shipments to be detained without physical examination. Refusal to permit an inspection, invalid registration, missing listing, unresolved CGMP deficiencies or a history of violative shipments can affect more than one product and more than one U.S. customer.
Geography does not reduce responsibility. A certificate issued by another country, compliance with European Union rules, ISO certification or lawful sale in the home market does not automatically establish compliance with U.S. FDA requirements. The U.S. classification, claims, label, manufacturing controls and import roles must be evaluated independently.
FDA communications and enforcement pathways
Inspection observations
At the conclusion of an inspection, FDA may issue observations on Form FDA 483. The form is not a final agency determination, but it requires prompt, factual and well-supported attention. A strong response identifies root causes, completed corrections, systemic corrective actions, responsible owners, timelines and effectiveness checks.
Untitled Letters
An Untitled Letter may identify violations that do not meet the threshold used for a Warning Letter. The lower level of formality should not be mistaken for low importance. The recipient should correct the conduct, preserve evidence and respond in a manner proportionate to the issue.
Warning Letters
Warning Letters communicate FDA’s position that significant violations exist and usually request prompt corrective action. They are often public. A response commonly must be submitted within the period stated in the letter, frequently fifteen working or business days, and should include documentation that enables FDA to evaluate the correction.
Detention and refusal
When an imported shipment appears to violate FDA law, the agency may issue a Notice of FDA Action designating the goods as detained. The owner or consignee may present testimony, records, relabeling or reconditioning proposals where legally available. A refusal is FDA’s final decision that the detained shipment is violative.
Import Alerts and DWPE
Import Alerts communicate conditions under which FDA field personnel may detain products without physical examination. Removal generally requires a persuasive submission showing that the conditions that gave rise to the problem have been corrected and that future shipments will comply.
Recall and judicial action
FDA may request or oversee a recall, issue public alerts and, depending on the law and facts, use mandatory authorities. The government may also pursue seizure, injunction or prosecution. A company should obtain qualified legal counsel when an issue may involve litigation, criminal exposure or privileged internal investigations.
Why weak corrective responses fail
- Promises without evidence: stating that employees were retrained or procedures were revised without providing records, revised documents, implementation evidence or effectiveness checks.
- Correction without root cause: fixing the observed batch, label or shipment but failing to determine why the quality system allowed the problem to occur.
- Too narrow a scope: addressing one product or line when the same deficient procedure affects other products, facilities, suppliers, laboratories or markets.
- Unrealistic timelines: promising immediate completion of validation, stability, facility upgrades or supplier remediation that cannot credibly be completed within the stated period.
- No interim controls: allowing manufacturing or distribution to continue without containment measures while permanent corrections remain open.
- Inconsistent statements: submitting a response that conflicts with batch records, import data, website claims, prior correspondence or information provided during an inspection.
- Delegating responsibility: blaming a contract manufacturer, consultant, laboratory, U.S. Agent, importer or broker without showing the firm’s own oversight and corrective action.
- Ignoring commercial channels: revising the package but leaving violative claims on Amazon, social media, distributor websites, brochures or influencer materials.
A corrective response should be technically sound, truthful and complete. It should distinguish immediate correction, product containment, root-cause analysis, corrective action, preventive action and effectiveness verification. The response should also clearly identify what remains open and when reliable completion evidence will be available.
Services provided by FDA consultants in the United States
A qualified consultant can add regulatory knowledge, structure and independent review. The regulated company, however, remains legally responsible for its products, decisions, records and ongoing compliance.
Regulatory assessment
Consultants may classify products, identify applicable statutes and regulations, verify facility and product obligations, review import roles and map gaps across manufacturing, labeling, records, complaints and marketing.
Inspection readiness
Services may include mock inspections, document-room preparation, interview coaching, inspection-response procedures, records inventories, facility walkthroughs and readiness exercises for domestic or foreign inspections.
Form FDA 483 and Warning Letter responses
A consultant may help organize observations, evaluate evidence, draft technical narratives, develop CAPA plans, define timelines and assemble exhibits. Regulatory counsel should be involved where legal strategy, privilege or enforcement exposure requires it.
Quality-system remediation
Consultants may revise SOPs, establish deviation and investigation systems, strengthen CAPA, improve supplier qualification, rebuild complaint programs, support validation and design training for management and operational personnel.
Labeling and claims review
Reviews can cover principal display panels, information panels, ingredient declarations, allergens, Nutrition or Supplement Facts, Drug Facts, device labeling, warnings, intended-use statements and online promotional claims.
Import detention assistance
Consultants may review Notices of FDA Action, entry data, labeling, test reports, registration records and proposed testimony. They may coordinate with importers, brokers, laboratories and counsel to support a timely, organized response.
Import Alert removal support
Assistance may include reviewing the reason for placement, preparing a remediation plan, evaluating compliant shipment evidence, coordinating audits and assembling a petition or request for removal consistent with the applicable criteria.
Registration and listing
Consultants may assist with food facility registration, U.S. Agent services, drug establishment registration and listing, medical device establishment registration and listing, cosmetic facility registration and product listing, and related updates.
Ongoing compliance programs
Retainer or periodic services may include regulatory monitoring, annual reviews, supplier verification, label-change control, complaint trending, recall exercises, training, renewal calendars and management compliance reports.
A practical remediation process
Protect consumers and contain affected product
Stop or control manufacturing, release, shipment, promotion or distribution when necessary. Identify affected lots, locations, import entries and customers. Evaluate whether reporting, market withdrawal, correction or recall action is required.
Preserve records and establish a response team
Protect paper and electronic records, laboratory data, emails, photographs, labels and supplier documents. Assign executive authority and include quality, regulatory, operations, import, legal and communications functions as appropriate.
Define the legal and technical scope
Confirm the affected products, establishments, requirements and markets. Determine whether the issue is isolated or systemic and whether related products, contract sites, labels, websites or importers are exposed.
Conduct documented root-cause analysis
Use a disciplined method that looks beyond operator error. Evaluate procedures, training, management oversight, incentives, workload, equipment, software, supplier controls, laboratory practices and change management.
Implement correction and CAPA
Separate immediate corrections from systemic corrective and preventive actions. Assign owners and deadlines, define objective completion evidence, institute interim controls and establish metrics for effectiveness.
Prepare a credible FDA submission
Answer every observation or allegation. Explain what happened, what was corrected, why the correction is adequate, what evidence is attached, what remains open and when additional information will be supplied. Avoid speculation and unsupported claims.
Verify sustainability
Audit implementation after the initial response. Review trends, deviations, complaints, batch outcomes, supplier performance and employee practices. Management should receive periodic reports until the system demonstrates lasting control.
Preventive compliance for international supply chains
Europe
Do not assume that EU conformity, CE marking, responsible-person arrangements or home-market labeling satisfy U.S. rules. Establish a U.S.-specific classification, claims, registration, listing, quality and import plan.
Asia
Control translations, private-label arrangements, contract factories, laboratory data and supplier changes. Ensure the legal manufacturer and actual production sites match FDA registrations, listings and import entries.
Latin America
Coordinate Spanish and Portuguese source documents with accurate English labels and U.S. records. Verify food process filings, allergen declarations, establishment identities and importer responsibilities before shipment.
Africa
Build documentation that can withstand remote review and inspection, including traceable suppliers, validated processes, reliable testing, complaint channels and prompt communication with U.S. representatives and importers.
For all regions, the most effective approach is to complete a U.S. regulatory review before production of commercial packaging and before the first shipment. Correcting a label, formulation, quality system or import role before launch is usually less disruptive than trying to repair it while goods are detained at a U.S. port.
FDA non-compliance is a management and systems problem
FDA compliance depends on daily execution. Registrations and filings matter, but they cannot compensate for an uncontrolled process, an inaccurate label, unsupported marketing, unreliable records or a company culture that postpones corrective action. Domestic and foreign firms should view compliance as an integrated business system linking executive responsibility, quality, regulatory affairs, manufacturing, logistics, import operations, sales and customer service.
When FDA identifies a violation, the first objective is to protect consumers and control affected product. The second is to understand the full scope and root cause. The third is to build and document corrections that FDA, customers and future inspectors can verify. A hurried letter that offers promises without evidence may worsen the situation, while a disciplined response can demonstrate that management recognizes the seriousness of the issue and is capable of sustainable remediation.
FDA consultants in the United States can help companies interpret requirements, prepare for inspections, assess labels, strengthen quality systems, respond to observations, support detained shipments and organize Import Alert removal efforts. Their work should be integrated with qualified legal counsel whenever enforcement strategy, litigation, criminal exposure or legal privilege is involved. Ultimately, no consultant, U.S. Agent, importer or broker replaces the regulated company’s obligation to comply.
Address FDA compliance risks before they interrupt your U.S. business
ITB HOLDINGS LLC assists domestic and foreign manufacturers, exporters, importers and distributors with FDA registration,U.S. Agent services, inspection readiness, labeling review, corrective-action planning, detention support and broader FDA compliance projects.
Assistance in Cases of FDA Non-Compliance
Professional assistance for manufacturers, exporters, importers and distributors responding to an FDA detention, regulatory concern or potential violation involving FDA-regulated products.
FDA Detention Assistance Service
An FDA detention can delay a shipment, create storage expenses, interrupt customer deliveries and expose future imports to additional regulatory scrutiny. A timely review of the detention notice and supporting documentation may help the responsible parties understand the reason for the FDA action and determine the appropriate next steps.
ITB HOLDINGS LLC provides an initial detention assistance service for domestic and foreign companies whose FDA-regulated products have been detained when offered for importation into the United States.
- Detention Notice Review Review of the available Notice of FDA Action and the stated reason for detention.
- Entry Information Review Preliminary review of available entry data, product information and manufacturer details.
- Compliance Document Review Review of documents supplied by the client, such as labels, registrations, listings, test reports or shipment records.
- Regulatory Issue Identification Identification of apparent compliance gaps that may have contributed to the detention.
- Recommended Next Steps General recommendations regarding documents, corrections or additional professional support that may be needed.
- Stakeholder Coordination Assistance communicating with the importer, customs broker, manufacturer, laboratory or other relevant parties.
Important: The Initial Service Fee does not automatically include laboratory testing, relabeling, reconditioning, preparation of extensive legal or scientific submissions, representation by an attorney, Import Alert removal work, recall management, travel or third-party expenses. Additional services may require a separate scope of work and service fee after the available documents have been reviewed.
